Abstract
Introduction: Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. treatment in hyperuricemic patients with chronic kidney disease (CKD) stage 3. with CKD grade 3 who are followed up by the pre-dialysis polyclinic. Around 67 of these patients administered allopurinol while 65 patients were not administered. The therapy protocol for the patients was allopurinol 150 mg/d and the duration of the follow-up was 12 months. Clinical records of the patients were screened, to start with 3, 6, 9 and 12 months, eGFR (estimated glomerular filtration rate) values were calculated. values. 12th month increased by 1.02 ± 8.89 mL/min/1.73 m2 from baseline in eGFR, but it was not statistically significant (P = 0.352). In the control group 12th month showed a decrease in baseline GFR value of 2.59 ± 7.9 mL/min/1.73 m2 (P = 0.012). The 3, 6, 9, 12th months compared with baseline in the allopurinol treatment group showed a significant decrease in uric acid value (P < 0.05). at stage 3 hyperuricemic CKD with allopurinol. The annual decline in GFR in hyperuricemic patients, is more than normouricemic patients.
Highlights
Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease
Patients and Methods A total of 132 chronic renal disease patients (41 female, 91 male) who were aged between 18-70 years, followed up by Nephrology Department of Antalya Research and Training Hospital between March 2011-September 2012, whose estimated glomerular filtration rate (GFR) was 30-60 mL/min/1.73 m2, who had hyperuricemia were enrolled in the study
Serum blood urea nitrogen (BUN), creatinine, albumin and uric acid levels tested with 3 months of intervals and estimated GFR (eGFR) values were calculated using modification of diet in renal disease (MDRD) formula
Summary
Hyperuricemia has been associated with the development of hypertension, cardiovascular, and renal disease. Objectives: We conducted a prospective study to investigate the benefits of allopurinol treatment in hyperuricemic patients with chronic kidney disease (CKD) stage 3. In the control group 12th month showed a decrease in baseline GFR value of 2.59 ± 7.9 mL/min/1.73 m2 (P = 0.012). The 3, 6, 9, 12th months compared with baseline in the allopurinol treatment group showed a significant decrease in uric acid value (P < 0.05). Conclusion: Decreased renal progression was observed by reduction of serum uric acid levels at stage 3 hyperuricemic CKD with allopurinol. Chronic kidney disease (CKD) is described as the presence of a renal disease lasting for more than 3 months, which is detected with biochemical analysis, urine analysis or imaging methods regardless of presence of reduced glomerular filtration rate (GFR) [1].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
